On December 19, 2024, Cardiol Therapeutics President and CEO, David Elsley, discussed the company's lead oral drug, CardiolRx, which is entering a late-stage Phase III clinical trial, MAVERIC. This trial targets patients with recurrent pericarditis who are at high risk for recurrence. Elsley emphasized that CardiolRx is uniquely positioned to address critical gaps in current treatment options for this condition.
Elsley highlighted the significant market opportunity for CardiolRx, stating its potential to be safer, more cost-effective, and disease-modifying. He believes CardiolRx could significantly improve the standard of care for thousands of patients living with recurrent pericarditis. The market for third-line recurrent pericarditis therapy in the US is estimated at approximately $500 million, with analyst forecasts exceeding $1 billion by 2028.
The MAVERIC program includes the Phase II MAvERIC-Pilot study, the Phase II/III MAVERIC-2 trial, and the planned Phase III MAVERIC-3 trial. CardiolRx has received US FDA Orphan Drug Designation for the treatment of pericarditis, which includes recurrent pericarditis. This strategic advancement into Phase III trials is a key milestone for the company's pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.